A clinical case of complex EGFRMUT treatment of NSCLC using targeted therapy with Osimertinib

Lung cancer is the most common malignant neoplasm and ranks first in the structure of cancer mortality. Lung cancer has long been thought to be a smoker’s disease and largely preventable by limiting tobacco use, but recent studies have shown an alarming increase in the incidence of the disease among non-smokers of both sexes. Personalized medicine, including careful molecular genetic testing, optimizes treatment for each patient and improves their quality of life during therapy.The subject of this article is a specific clinical case of the effective use of Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), which has been widely used as first-line therapy in patients with metastatic EGFR-mutant non-small cell lung cancer (NSCLC), and currently shows excellent results in the adjuvant mode. The aim of the work is to analyze the effectiveness of the use of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in lung adenocarcinoma using an example from clinical practice. During the discussion of the specifics of treatment of a patient with NSCLC, the results of laboratory tests, data from various diagnostic and treatment methods are used.